Publication

Xultophy : combination therapy for the treatment of type 2 diabetes

Chaplin, Steve
; 
Abstract
Xultophy is the first product to combine a basal insulin and an incretin mimetic for the treatment of type 2 diabetes. Here Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Vinod Patel outlines its place in therapy.
MIDER Authors
Patel, Vinod
Citations
Altmetric:
Date
2015-09-04
Type
Article
Subject
Diabetes, Pharmacology
Collections
GEH Diabetes and Endocrinology
Show all metadata
Citation
Chaplin S, Patel V. Xultophy: Combination therapy for the treatment of type 2 diabetes. Prescriber. 2015 September;26(17):32-34. doi: 10.1002/psb.1382.
Journal / Source Title
Prescriber
DOI
10.1002/psb.1382
URI
http://hdl.handle.net/20.500.14200/7361
PMID
Publisher
Wiley
Publisher’s URL
Publisher’s statement
Note / Copyright